Autoimmune Diseases
Welcome,         Profile    Billing    Logout  
 293 Companies   491 Products   491 Products   198 Mechanisms of Action   26 Trials   7806 News 


«12345678910111213...156157»
  • ||||||||||  teriflunomide / Generic mfg.
    Trial completion, Enrollment change, Trial completion date, Trial primary completion date:  Teriflunomide Male Transmission Study (clinicaltrials.gov) -  Jan 2, 2019   
    P=N/A,  N=20, Completed, 
    Recruiting --> Completed | N=40 --> 20 | Trial completion date: Dec 2017 --> Sep 2018 | Trial primary completion date: Oct 2017 --> Aug 2018
  • ||||||||||  Enrollment change, Trial completion date, Trial termination, Trial primary completion date:  Evaluation of Automated Insulin Pump Settings Using the Advisor Pro (Previously Called) MD-Logic Pump Advisor-three Segments Study (clinicaltrials.gov) -  Dec 21, 2018   
    P=N/A,  N=50, Terminated, 
    Trial completion date: Nov 2018 --> Nov 2019 | Trial primary completion date: Aug 2018 --> Feb 2019 N=220 --> 50 | Trial completion date: Apr 2019 --> Dec 2018 | Recruiting --> Terminated | Trial primary completion date: Apr 2019 --> Dec 2018; The required data was obtained and there was no need to collect further data
  • ||||||||||  Trial completion, Video:  Video Game-based Therapy for Arm Weakness In Progressive Multiple Sclerosis (clinicaltrials.gov) -  Dec 21, 2018   
    P=N/A,  N=31, Completed, 
    N=220 --> 50 | Trial completion date: Apr 2019 --> Dec 2018 | Recruiting --> Terminated | Trial primary completion date: Apr 2019 --> Dec 2018; The required data was obtained and there was no need to collect further data Active, not recruiting --> Completed
  • ||||||||||  Kineret (anakinra) / SOBI
    Enrollment change, Trial termination, Trial primary completion date:  TRACK: Clinical Study to Evaluate the Efficacy of Anakinra in Patients With Rheumatoid Arthritis and Diabetes (clinicaltrials.gov) -  Dec 14, 2018   
    P4,  N=41, Terminated, 
    N=178 --> 0 | Trial completion date: Dec 2020 --> Dec 2019 | Not yet recruiting --> Withdrawn | Trial primary completion date: May 2020 --> Dec 2019 N=200 --> 41 | Recruiting --> Terminated | Trial primary completion date: Jul 2015 --> Dec 2017; Decision of the Sponsor for Early Benefits
  • ||||||||||  Betaseron (IFN-β-1b) / Bayer
    Phase classification:  Betaseron Pregnancy Registry (clinicaltrials.gov) -  Dec 12, 2018   
    P=N/A,  N=113, Completed, 
    Active, not recruiting --> Terminated Phase classification: P4 --> P=N/A
  • ||||||||||  Enbrel (etanercept) / Pfizer, Amgen
    Trial completion, Trial completion date, Trial primary completion date:  Niclosamide With Etanercept in Rheumatoid Arthritis (clinicaltrials.gov) -  Dec 12, 2018   
    P1/2,  N=110, Completed, 
    Phase classification: P4 --> P=N/A Recruiting --> Completed | Trial completion date: Apr 2019 --> Dec 2018 | Trial primary completion date: Apr 2019 --> Aug 2018
  • ||||||||||  Trial completion, Enrollment change, Trial completion date, Trial primary completion date:  Screening of Subjects With Type I Diabetes to Determine Eligibility for Islet Transplantation (clinicaltrials.gov) -  Dec 11, 2018   
    P=N/A,  N=40, Completed, 
    Recruiting --> Completed | Trial completion date: Apr 2019 --> Dec 2018 | Trial primary completion date: Apr 2019 --> Aug 2018 Recruiting --> Completed | N=600 --> 40 | Trial completion date: Dec 2020 --> Nov 2018 | Trial primary completion date: Apr 2020 --> Nov 2018
  • ||||||||||  tibulizumab (ZB-106) / Zura Bio
    Trial completion:  A Study of LY3090106 in Participants With Sj (clinicaltrials.gov) -  Dec 11, 2018   
    P1,  N=32, Completed, 
    Recruiting --> Completed | N=600 --> 40 | Trial completion date: Dec 2020 --> Nov 2018 | Trial primary completion date: Apr 2020 --> Nov 2018 Active, not recruiting --> Completed
  • ||||||||||  Kinaction (masitinib) / AB Science
    Trial completion date, Combination therapy:  Masitinib in Refractory Active Rheumatoid Arthritis (clinicaltrials.gov) -  Dec 10, 2018   
    P2b,  N=324, Terminated, 
    Phase classification: P2 --> P2a Trial completion date: Jun 2018 --> Sep 2016
  • ||||||||||  Kinaction (masitinib) / AB Science
    Trial completion date, Trial primary completion date, Combination therapy:  Masitinib in Refractory Active Rheumatoid Arthritis (clinicaltrials.gov) -  Dec 6, 2018   
    P2b,  N=324, Terminated, 
    Active, not recruiting --> Completed Trial completion date: Dec 2015 --> Jun 2018 | Trial primary completion date: Dec 2013 --> Jun 2018
  • ||||||||||  Trial completion:  Hybrid Closed Loop Pivotal Trial in Type 1 Diabetes (clinicaltrials.gov) -  Dec 4, 2018   
    P=N/A,  N=124, Completed, 
    Phase classification: P2 --> P2a Active, not recruiting --> Completed
  • ||||||||||  Enrollment change, Trial completion date, Trial termination, Trial primary completion date:  MESEMS: MEsenchymal StEm Cells for Multiple Sclerosis (clinicaltrials.gov) -  Dec 3, 2018   
    P1/2,  N=1, Terminated, 
    Active, not recruiting --> Completed N=12 --> 1 | Trial completion date: May 2018 --> Dec 2017 | Recruiting --> Terminated | Trial primary completion date: May 2018 --> Dec 2017; inclusion default
  • ||||||||||  clindamycin phosphate / Generic mfg.
    Trial completion, Enrollment change, Trial completion date, Trial primary completion date:  ESPERA: Therapeutic Management of Periodontitis and Clinical Manifestations of Rheumatoid Arthritis (clinicaltrials.gov) -  Dec 3, 2018   
    P=N/A,  N=22, Completed, 
    N=12 --> 1 | Trial completion date: May 2018 --> Dec 2017 | Recruiting --> Terminated | Trial primary completion date: May 2018 --> Dec 2017; inclusion default Recruiting --> Completed | N=40 --> 22 | Trial completion date: Dec 2017 --> Nov 2016 | Trial primary completion date: Dec 2017 --> Nov 2016
  • ||||||||||  Cimzia (certolizumab pegol) / Astellas, UCB
    Trial completion:  NIMRA: Novel Imaging Markers for Rheumatoid Arthritis (clinicaltrials.gov) -  Nov 30, 2018   
    P=N/A,  N=30, Completed, 
    Recruiting --> Completed | N=40 --> 22 | Trial completion date: Dec 2017 --> Nov 2016 | Trial primary completion date: Dec 2017 --> Nov 2016 Active, not recruiting --> Completed
  • ||||||||||  Trial completion, Enrollment change, Trial primary completion date:  A Task-oriented Circuit Training in Multiple Sclerosis (clinicaltrials.gov) -  Nov 29, 2018   
    P=N/A,  N=35, Completed, 
    Active, not recruiting --> Completed Recruiting --> Completed | N=60 --> 35 | Trial primary completion date: Mar 2018 --> Oct 2018
  • ||||||||||  Trial completion date, Trial termination, Trial primary completion date:  AIRSEP: Fatigue and Inspiratory Muscles Training in Patients With Multiple Sclerosis (clinicaltrials.gov) -  Nov 23, 2018   
    P=N/A,  N=46, Terminated, 
    N=60 --> 0 | Trial completion date: Oct 2019 --> Nov 2018 | Not yet recruiting --> Withdrawn | Trial primary completion date: Oct 2019 --> Nov 2018 Trial completion date: May 2019 --> Nov 2018 | Recruiting --> Terminated | Trial primary completion date: Aug 2018 --> May 2018; lack of recruitment
  • ||||||||||  Enrollment change:  PAS:IDE: Post-PMA Approval Study: 10 Year Follow-Up IDE Subjects (clinicaltrials.gov) -  Nov 21, 2018   
    P=N/A,  N=231, Completed, 
    Trial completion date: May 2019 --> Nov 2018 | Recruiting --> Terminated | Trial primary completion date: Aug 2018 --> May 2018; lack of recruitment N=350 --> 231
  • ||||||||||  Trial completion, Trial completion date, Trial primary completion date:  BARDA II: Identify Clinical Conditions That Increase Circulating DNA Levels (clinicaltrials.gov) -  Nov 21, 2018   
    P=N/A,  N=130, Completed, 
    N=350 --> 231 Active, not recruiting --> Completed | Trial completion date: Jul 2019 --> Jul 2016 | Trial primary completion date: Oct 2018 --> Jul 2016
  • ||||||||||  Trial completion, Enrollment change, Trial completion date, Trial primary completion date:  TMP001 in Relapsing-remitting Multiple Sclerosis (clinicaltrials.gov) -  Nov 21, 2018   
    P2a,  N=9, Completed, 
    Active, not recruiting --> Completed | Trial completion date: Jul 2019 --> Jul 2016 | Trial primary completion date: Oct 2018 --> Jul 2016 Recruiting --> Completed | N=55 --> 9 | Trial completion date: Dec 2017 --> Apr 2018 | Trial primary completion date: Dec 2017 --> Apr 2018
  • ||||||||||  Trial completion, Enrollment change, Trial initiation date:  Topical Tripterygium Wilfordii Gel for Moderate Activity Rheumatoid Arthritis (clinicaltrials.gov) -  Nov 20, 2018   
    P=N/A,  N=70, Completed, 
    Active, not recruiting --> Completed Active, not recruiting --> Completed | N=168 --> 70 | Initiation date: Jun 2016 --> Apr 2012
  • ||||||||||  Trial completion, Trial completion date, Trial primary completion date:  PAS:IDE: Post-PMA Approval Study: 10 Year Follow-Up IDE Subjects (clinicaltrials.gov) -  Nov 19, 2018   
    P=N/A,  N=350, Completed, 
    Active, not recruiting --> Completed | N=168 --> 70 | Initiation date: Jun 2016 --> Apr 2012 Active, not recruiting --> Completed | Trial completion date: Mar 2018 --> Aug 2017 | Trial primary completion date: Mar 2018 --> Jun 2017
  • ||||||||||  Actemra IV (tocilizumab) / Roche, JW Pharma
    Trial completion, Trial primary completion date:  Immunoregulatory Mechanisms of Treg Cells Induced by Tocilizumab (clinicaltrials.gov) -  Nov 14, 2018   
    P=N/A,  N=35, Completed, 
    Recruiting --> Active, not recruiting Recruiting --> Completed | Trial primary completion date: Mar 2018 --> Oct 2018
  • ||||||||||  Remicade (infliximab) / J&J
    Trial completion date, Trial primary completion date:  HARIR: Tracking Biologics Along the Silk Road (clinicaltrials.gov) -  Nov 2, 2018   
    P=N/A,  N=140, Active, not recruiting, 
    Not yet recruiting --> Completed | Trial completion date: Dec 2017 --> Oct 2018 Trial completion date: Dec 2019 --> Dec 2018 | Trial primary completion date: Dec 2019 --> Dec 2018
  • ||||||||||  fingolimod / Generic mfg.
    Trial completion, Enrollment change, Trial completion date:  Biologic Basis for Multiple Sclerosis Disease Progression in RRMS Patients Treated With Gilenya (clinicaltrials.gov) -  Nov 1, 2018   
    P=N/A,  N=135, Completed, 
    Trial completion date: Dec 2019 --> Dec 2018 | Trial primary completion date: Dec 2019 --> Dec 2018 Active, not recruiting --> Completed | N=100 --> 135 | Trial completion date: Feb 2018 --> Oct 2018
  • ||||||||||  Humalog pen (insulin lispro) / Eli Lilly
    Trial completion:  Environmental Effects Type 1 Diabetes Mellitus (clinicaltrials.gov) -  Oct 31, 2018   
    P=N/A,  N=10, Completed, 
    Active, not recruiting --> Completed Recruiting --> Completed
  • ||||||||||  Trial completion, Trial completion date, Trial primary completion date:  A Trial to Compare the Effectiveness of Two Rehabilitation Programs for Multiple Sclerosis Patients (clinicaltrials.gov) -  Oct 23, 2018   
    P=N/A,  N=240, Completed, 
    Recruiting --> Completed | N=100 --> 35 | Trial completion date: Mar 2019 --> Nov 2017 | Trial primary completion date: Mar 2018 --> Nov 2017 Recruiting --> Completed | Trial completion date: May 2018 --> Oct 2017 | Trial primary completion date: Nov 2017 --> Apr 2017
  • ||||||||||  Actemra IV (tocilizumab) / Roche, JW Pharma
    Enrollment change, Trial completion date, Trial termination, Trial primary completion date:  A Study of the Efficacy and Safety of Tocilizumab for Confirmed Rheumatoid Arthritis (RA) Participants in Clinical Practice (clinicaltrials.gov) -  Oct 18, 2018   
    P=N/A,  N=8, Terminated, 
    Enrolling by invitation --> Completed | N=1920 --> 1276 N=413 --> 8 | Trial completion date: Jul 2018 --> Dec 2017 | Recruiting --> Terminated | Trial primary completion date: Jul 2018 --> Dec 2017; Planned recruitment target not reached
  • ||||||||||  PEC-Direct (PEC-01) / Vertex
    Trial completion, Enrollment change, Trial completion date, Trial primary completion date:  A Safety and Tolerability Study of VC-02 (clinicaltrials.gov) -  Oct 18, 2018   
    P1,  N=3, Completed, 
    N=413 --> 8 | Trial completion date: Jul 2018 --> Dec 2017 | Recruiting --> Terminated | Trial primary completion date: Jul 2018 --> Dec 2017; Planned recruitment target not reached Active, not recruiting --> Completed | N=15 --> 3 | Trial completion date: Jun 2018 --> Feb 2018 | Trial primary completion date: Jun 2018 --> Feb 2018